Sernova (XTER:PSH) Capex-to-Operating-Income

: 0.00 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Sernova's Capital Expenditure for the three months ended in Jan. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Jan. 2024 was C$-10.03 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Sernova Capex-to-Operating-Income Historical Data

The historical data trend for Sernova's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Sernova Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Sernova's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova Capex-to-Operating-Income Distribution

For the Biotechnology industry and Healthcare sector, Sernova's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Sernova's Capex-to-Operating-Income falls into.

Sernova Capex-to-Operating-Income Calculation

Sernova's Capex-to-Operating-Income for the fiscal year that ended in Oct. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.099)	/	-40.502
	=	N/A

Sernova's Capex-to-Operating-Income for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-10.028
	=	N/A

Sernova (XTER:PSH) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Sernova Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Sernova's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova (XTER:PSH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (XTER:PSH) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

SEOVF:USA PSH:Germany SVA:Canada

Address

700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.

Sernova (XTER:PSH) Capex-to-Operating-Income

Sernova Capex-to-Operating-Income Historical Data

Sernova Capex-to-Operating-Income Calculation

Sernova Capex-to-Operating-Income Related Terms

Sernova (XTER:PSH) Business Description

Sernova (XTER:PSH) Headlines